Primary Bone Lymphoma: A Retrospective Analysis of 22 Patients Treated in a Single Tertiary Center

Alexios Matikas\textsuperscript{a} \ Alexandros Briasoulis\textsuperscript{b} \ Ifigeneia Tzannou\textsuperscript{a} \ Dimitra Oikonomopoulou\textsuperscript{a} \ Maria Bakiri\textsuperscript{a} \ Themis Karmiris\textsuperscript{a} \ Nikolaos Harhalakis\textsuperscript{a}

\textsuperscript{a}Lymphoma, Hematology and Bone Marrow Transplant Department, Evangelismos General Hospital, Athens, Greece; and \textsuperscript{b}University of Chicago Medicine, Chicago, Ill., USA

Introduction

Primary bone lymphoma (PBL) was recognized as a distinct entity for the first time in 1939 by Parker and Jackson \cite{1}. The definition of PBL varies depending on the author; some include only patients with Ann Arbor stage I and II disease \cite{2} and others also include stage IV patients \cite{3}. PBL is a rare malignancy, accounting for 3\% of all primary malignant bone tumors in adults \cite{4}, 2\% of all lymphomas \cite{5} and less than 5\% of all extra-nodal non-Hodgkin lymphomas (NHL) \cite{6}.

In most series, PBL is usually diagnosed between the ages 50–70 and there is a male predominance. The most common histologic subtype is diffuse large B-cell lymphoma (DLBCL) \cite{7}.
phoma (DLBCL); other rarer histologies have been consistently reported. Over the years, the treatment of PBL has evolved; from monotherapy with radiotherapy to combination chemotherapy or combined modality therapy and more recently to immunochemotherapy with the addition of the anti-CD20 monoclonal antibody rituximab. The 5-year overall survival has also improved along with the optimization of treatment strategies [7].

In the present study we aim to examine the clinicopathologic characteristics of all the cases of PBL that were treated at our institution during the past two decades, determine the outcome and assess whether the newer immunochemotherapy regimens affect the prognosis. We also briefly review the available literature.

**Patients and Methods**

**Definition of PBL**

WHO classifies PBL into four groups [8]; Group A: lymphoma involving a single bone site with or without regional lymph node involvement. Group B: lymphoma involving multiple bones but with no evidence of other disease sites. Group C: lymphoma involving a bone site at the presence of disseminated lymph node or visceral disease. Group D: lymphoma involving any part of the body, diagnosed by bone biopsy performed to rule out possible involvement. In our search we included patients belonging to groups A and B.

**Patients**

We retrospectively searched the electronic records of the Lymphoma Unit, Hematology Lymphoma and Bone Marrow Transplant Department, Evangelismos Athens General Hospital for patients who had received a diagnosis of primary bone lymphoma during the period 1992–2012. We identified 24 patients and collected data from 22. 2 were excluded from our analysis, 1 because the patient transferred his treatment to another hospital and another because of incomplete data. In all the cases there was pathological confirmation of the diagnosis. We collected and analyzed data regarding the patients’ age, sex, site of disease, presenting symptoms, stage, histologic subtype, International Prognostic Index (IPI), first line treatment, response to treatment and overall survival.

**Staging and Response Assessment**

Staging was performed according to the Ann Arbor system. Patients with disease involving a single bone site were categorized as stage IE (WHO Group A). In case of regional lymph node involvement, they were categorized as stage IIE. Finally, stage IVE included patients with multiple bone involvement without evidence of distant nodal or visceral disease (WHO Group B). Stage IIIIE patients, defined as those with distant nodal disease were excluded from the definition of PBL.

Assessment of response to treatment was defined according to the International Workshop Criteria (IWRC) [9]. Complete response (CR) was defined as disappearance of all detectable clinical and radiographic evidence of disease, excluding abnormalities attributed to bone remodeling. Partial response (PR) was defined as a ≥50% reduction of all measurable tumors. Progressive disease (PD) was defined as a ≥50% in the size of previously involved sites or the appearance of new lesions despite therapy. Finally, stable disease (SD) was defined as a response lesser than PR but not fulfilling the PD criteria.

Staging and response assessment investigations included complete blood count, blood chemistry including LDH, bone marrow biopsy and imaging studies: magnetic resonance imaging (MRI) and/or computed tomography (CT) in all the patients; gallium scans in most and FDG-PET scans (Positron Emission Tomography) in the most recent cases after 2007, when the technique became available at our institution.

For comparative purposes, patients were divided in two groups, according to the chemotherapy regimen they received. In the first group there were the patients treated in the pre-rituximab era that had received with either CHOP-like (cyclophosphamide, doxorubicin, vincristine and prednisolone) or third generation regimens such as ProMACE Cyta-BOM (cyclophosphamide, doxorubicin, etoposide, bleomycin, vincristine, methotrexate and prednisolone). In the second group there were the patients that had been treated with R-CHOP-like (rituximab + CHOP) immunochemotherapy regimens.

**Statistical Analysis**

All statistical analyses were performed with SPSS (version 19.0; SPSS, Chicago, Ill., USA). All variables were tested for normal distribution of the data. The analyses were performed on an intention-to-treat and on-treatment basis. Normally distributed data were expressed as means ± SD. For categorical variables, the χ² or Fisher exact test, were used to compare the distributions of the groups. Nonparametric tests were used for between-group comparisons of continuous variables. Non-normally distributed data were presented as the median with the interquartile range. The Kaplan–Meier method was used to estimate the survival distributions. The log-rank test was used to compare the survival distributions. All significance tests were 2 tailed and conducted at the 5% significance level.

**Results**

**Patient Characteristics**

The demographic and clinical characteristics of the patients are shown on table 1. The median age was 55 years (range: 19–83 years), with a 1.2:1 male to female ratio. 14 reported pain as one of their initial symptoms, 2 presented with fractures, 2 because of skin ulcers, 3 because of a palpable mass and only one patient reported B symptoms (fever, sweats, weight loss) as part of his initial symptoms.

The most common site of disease was the spine (n = 11, 50%) followed by the extremities (n = 7, 31.8%) and the jaw (n = 4, 18.1%). Most patients presented with Ann Arbor stage IE disease (n = 16, 72.7%) compared to stage...
IIE (n = 3, 13.6%) and stage IV disease (n = 3, 13.6%). Most patients had a low IPI score (0–1: 63.6%), indicating a good prognosis.

DLBCL was the most common histopathological subtype (n = 18, 81.8%), the majority being of the Germinal center-like type. Other subtypes included a case of lymphoplasmacytic lymphoma (LPC), one T-cell lymphoma, one MALT lymphoma and a NHL not otherwise specified (NOS) because the patient had received radiotherapy before a biopsy was performed, due to spinal cord compression.

Initial Treatment, Response and Survival

Out of the 22 patients, 21 underwent chemotherapy and one patient was treated with radiotherapy alone. The majority of the chemotherapy-treated patients received CHOP or a variation (9 patients). 2 patients received the ProMACE Cyta-BOM regimen and 10 patients were treated with R-CHOP or R-mini-CHOP (R-CHOP with half the doxorubicin dose). Patients received a mean of 5.71 chemotherapy cycles (range: 4–7). 8 patients were treated with additional intrathecal methotrexate for CNS prophylaxis (range: 2–7 infusions). 17 patients were treated with radiotherapy; one as a monotherapy and 16 as part of a combined modality therapy. The median dose received was 37 Gy (range: 30–50 Gy).

According to IWRC criteria, 18/22 patients (81.8%) attained a complete response, 1/22 (4.5%) a partial response, 1 patient had stable disease (4.5%) and finally 2 patients progressed during first line treatment (9%). Among the 19 responders one relapsed in the CNS and 4 had a systematic relapse.

Among the 6 cases with PBL who were deceased at the time of data extraction and analysis the median time to death after the diagnosis of PBL was 66.5 months (mean 86.8, range 4–180 months) (fig. 1). In that subgroup of patients with PBL causes of death were all lymphoma related. Among the 16 cases alive at the last follow-up visit, the median follow-up duration was 52 months (mean 55.46, range 9–136 months). The overall 1-, 5- and 10-year survival rates of the 22 cases were 95.5, 86.3, 81.8%, respectively. We compared the survival rate of patients following different treatments. Univariate analysis revealed that the overall survival rate was not significantly different between patients treated with R-CHOP and those treated with older chemotherapy regimens (χ² 0.291, p = 0.589; fig. 2). We also sought to identify parameters that affected overall survival. Univariate analysis revealed that patients aged less than 50 years old had a better survival than those aged over 50 years old, a difference that bordered but did not reach significance (p = 0.097). Survival was affected by the response to initial treatment: patients attaining a complete or partial response had a significantly longer overall survival (p < 0.0001). Stage, gender, histology, IPI score and use of radiotherapy were not found to be prognostic indicators in our series.
Table 2. Summary of all the PBL series of the past decade

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Median age</th>
<th>Stage I–II</th>
<th>ORR</th>
<th>OS, % years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinzani 2003 [16]</td>
<td>52</td>
<td>58</td>
<td>79</td>
<td>90</td>
<td>68 (9)</td>
</tr>
<tr>
<td>Stein 2003 [19]</td>
<td>19</td>
<td>54</td>
<td>58</td>
<td>89</td>
<td>NA</td>
</tr>
<tr>
<td>Barbieri 2004 [22]</td>
<td>77</td>
<td>42</td>
<td>100</td>
<td>95</td>
<td>88</td>
</tr>
<tr>
<td>Horsman 2006 [23]</td>
<td>37</td>
<td>55</td>
<td>100</td>
<td>57</td>
<td>64</td>
</tr>
<tr>
<td>Ramadan 2007 [17]*</td>
<td>131</td>
<td>63</td>
<td>46</td>
<td>84</td>
<td>62 (5)</td>
</tr>
<tr>
<td>Jawad 2010 [7]</td>
<td>1,500</td>
<td>NA</td>
<td>69.1</td>
<td>NA</td>
<td>58 (5)</td>
</tr>
<tr>
<td>Alencar 2010 [24]</td>
<td>53</td>
<td>52</td>
<td>77</td>
<td>85</td>
<td>83 (4)</td>
</tr>
<tr>
<td>Pellegrini 2011 [25]</td>
<td>21</td>
<td>34</td>
<td>NA</td>
<td>95</td>
<td>95 (8)</td>
</tr>
<tr>
<td>Nasiri 2011 [26]</td>
<td>28</td>
<td>41</td>
<td>75</td>
<td>NA</td>
<td>54 months</td>
</tr>
<tr>
<td>Cai 2012 [27]</td>
<td>116</td>
<td>50</td>
<td>100</td>
<td>91</td>
<td>76 (5)</td>
</tr>
<tr>
<td>Kim 2012 [28]</td>
<td>33</td>
<td>40</td>
<td>39</td>
<td>88</td>
<td>166 months</td>
</tr>
</tbody>
</table>

ORR = Overall response; OS = overall survival.
* Response rate and survival only for patients with DLBCL.
Discussion

Primary bone lymphoma is a rare disease and thus, the design and completion of prospective studies is challenging, meaning that experience in the literature comes from small retrospective case series.

In our series, DLBCL was the most common histopathologic subtype in accordance to other series [10]. However, almost any lymphoma histology has been reported causing primary bone disease, including low grade histologies, anaplastic lymphoma [11] and Burkitt lymphoma [12]. Interestingly, the sites of occurrence differ among the various studies: in two series of Japanese patients, PBL most commonly involved the pelvis, [13, 14] in others the most common sites of disease were the long bones, [15, 16] another study of 131 patients of the British Columbia Cancer Agency reported equal frequency between axial and extremity involvement [17] and finally the SEER database study reported a predominance of axial involvement among 1,500 PBL patients [7], a finding our study shares.

Radiotherapy was first used in the treatment of PBL 40 years ago, achieving for the first time disease control [18]. Combination chemotherapy results in durable responses but no prospective randomized studies have been performed to optimize treatment strategies. In a retrospective series of 52 consecutive patients, 85% of the patients that received chemotherapy with or without radiotherapy attained a complete response, compared to 64% of those that were treated with radiotherapy alone [16]. The effect of combined modality treatment (chemoradiotherapy) was positive in another series of 82 patients: 5-year survival rate was 95% compared to 78% of the single modality approach (p = 0.013) [3]. However, the study of the British Columbia Cancer Agency reported conflicting results [17]. More recently, the introduction of the anti-CD20 monoclonal antibody rituximab has transformed the treatment of non-Hodgkin lymphomas. The large number of small retrospective studies that report conflicting results hinders our ability to draw conclusions regarding the effect of rituximab in the overall survival of PBL patients [17, 24, 25, 28].

The prognosis of PBL is relatively good and on a par with stage-systemic DLBCL. In our series, the 5-year survival rate was 86.3% and we found that it was affected by the patients’ age and response to first line treatment. The reported 5-year survival rates vary greatly, from 60% for the patients diagnosed after 1996 in the SEER database study up to 95.2% in a series published by Pellegrini et al. [7, 25]. Moreover, various studies report different prognostic factors, such as age [7], sex [3], stage [17], lactate dehydrogenase levels [3], histologic subtype [13] and IPI [17], even though the Memorial Sloan–Kettering Cancer Center study concluded that IPI status did not affect the prognosis [3]. Table 2 summarizes all the PBL series that were published in the literature during the past 10 years when use of immunochemotherapy became widespread in the treatment of non-Hodgkin lymphomas.

In conclusion, we retrospectively analyzed data from 22 primary bone lymphoma patients treated at our institution during the past 20 years and we briefly reviewed the available literature. However, carefully designed prospective studies are needed that will help clarify many aspects of the disease.

Acknowledgements

The authors would like to express their gratitude to Dr Nikos Papageorgiou for his valuable contributions throughout the preparation of this manuscript.

References